Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Presence of NDMA impurity detected in product.
| Distributed by / for | Denton Pharma, Inc. |
| NDC | 70934-017-04 |
| Full product label | Ranitidine Tablets, USP 150 mg , a). 4 count bottle (NDC 70934-017-04), b). 20-count bottle (NDC 70934-017-20), c). 24-count bottle (NDC 70934-017-24) d). 30-count bottle (NDC 70934-017-30) e). 90-count bottle (NDC 70934-017-90), Rx Only, Repackaged by: Northwind Pharmaceuticals North Brenheim, NY 12131. |
| Recalling firm | Denton Pharma, Inc. |
| Distribution | Nationwide |
| Quantity | 1,341 bottles |
| Recall initiated | 2019-12-20 |
| Report date | 2020-01-29 |
| Recall completed | 2023-10-05 |
| Recall number | D-0794-2020 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | North Blenheim NY United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗